Kamel Khalili, PhD, Laura H. Carnell Professor and Chair of the Department of Neuroscience, and Director of the Center for Neurovirology and the Comprehensive NeuroAIDS Center at the Lewis Katz School of Medicine at Temple University (LKSOM), will lead a project at LKSOM evaluating the medication Piclidenoson and its effect on the viral load of coronaviruses in a mammalian cell model system. Piclidenoson is currently undergoing a Phase III clinical trial to treat rheumatoid arthritis. It has previously demonstrated anti-viral activity against HIV, which is a single-stranded RNA virus – as are coronaviruses. Pharmaceutical Technology covered the news.
Temple Faculty Physicians is experiencing technical issues with phone lines. If you are experiencing an emergency, please visit your nearest emergency room. If you would like to schedule an appointment with your provider or have general questions or requests, please contact us by using myTempleHealth.
myTempleHealth
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH
Related News
Celebrating Life, and Transplant Excellence, at the Ballpark
Posted April 23, 2024There are few things as exciting as throwing out the first pitch at a Phillies game. But at the top of the list is knowing you’ve got a second chance at life.
Read More310 Temple Health Physicians Named ‘Top Doctors’ by Philadelphia Magazine
Posted April 22, 2024These Temple Health physicians practice at Main Campus, Fox Chase, Jeanes Campus, Episcopal Campus, Chestnut Hill Hospital, Temple Physicians, Inc. and Fair Hill Community Physicians.
Read More